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Oxolanosterol oximes: dual-action inhibitors of
cholesterol biosynthesis
Leah L. Frye,' Kevin P. Cusack, Deborah A. Leonard, and Jeffrey A. Anderson
Department of Chemistry, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, and Biology
Department, West Virginia University, Morgantown, WV 26506-6057

Abstract A series of oxolanosterol oximes and oxime ethers
have been prepared as potential dual-action inhibitors of cholesterol biosynthesis. The synthesis of these oximes along with the
evaluation of their ability to inhibit lanosterol 14a-methyl demethylase (P450DM) and to suppress 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGR) activity is presented. 38Hydroxylanost-7-en-15-one
15-oxime XIX was found to be an
effective inhibitor of P450DM in rat liver microsomal preparations. In [ "Clacetate incorporation studies using Chinese hamster ovary (CHO) cells, compound XIX was found to cause a
dramatic reduction in the incorportion of acetate into C2, sterols
with a concommitant increase in radiolabeled C3,,sterols which
is consistent with the inhibition of P450DM.In addition, 15oxime XIX was shown to suppress HMGR activity in both wildtype CHO and P450DM-deficient(AR45) cells, indicating that
suppression of HMGR is independent of any effects of this
oxime on P450DM. In both cell lines, parallel declines in
HMGR activity and HMGR protein levels were observed suggesting that compound XIX suppresses HMGR activity by
regulation of gene expression. IThese results demonstrate
that, as predicted, 15-oxime XIX is indeed a dual-action inhibitor of cholesterol biosynthesis which causes both the inhibition
of P 4 5 0 and
~ ~ a reduction in HMGR activity.-Frye, L. L.,
K. P. Cusack, D. A. Leonard, and J. A. Anderson. 0x0lanosterol oximes: dual-action inhibitors of cholesterol biosynthesis. J. Lipid Res. 1994. 35: 1333-1344.
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T h e rate-limiting step of overall cholesterol biosynthesis
coenz'yme A
is catalyzed by 3-hydroxy-3-methylglutaryl
reductase (HMGR). This enzyme catalyzes the reduction
coenzyme A (HMG-CoA)
of 3-hydroxy-3-methylglutaryl
to yield meValonate
The activity Of HMGR appears
to be regulated through a multivalent feedback mecha,.,ism mediated by o x y ~ t e r o ~along
s
with another metabolite of mevalonate (4-8). T h e prototypical oxysterol,
25-hydroxycholesterol I, appears to regulate HMGR activity primarily via a transcriptional mechanism involving
a 42 base-pair
in the 5' flanking region Of the
gene (9) (Scheme 1). However, recent studies indicate

that some oxysterols, particularly oxylanosterols, may be
involved in post-transcriptional regulation of HMGR
synthesis (10, 11).
Of the numerous oxysterols that have been studied as
suppressors of HMGR activity, a limited number were
found to be more potent in the inhibition of overall
cholesterol biosynthesis than could be explained by their
ability to suppress HMGR activity. Two of these, 14aethylcholest-7-ene-3~,15a-diol
I1 (12-14) and 3P-hydroxylanost-7-en-15-one I11 (15, IS), were found to inhibit the
conversion of lanosterol IV (or dihydrolanosterol XI)
(Scheme 2) to cholesterol, which suggests that they are
also inhibitors of lanosterol 14a-methyl demethylase
(P45oDM), the cytochrome P450 monooxygenase that
catalyzes the first step in the conversion of lanosterol IV
to cholesterol. A novel carboxylic acid analog of lanosterol
(compound V) has also been reported to be a potent
inhibitor of P45oDM and a suppressor of HMGR activity
(17). Recently, we reported the synthesis and evaluation of
compounds VIa&b and VI1 (18, 19). As anticipated,
these compounds were found both to inhibit P 4 5 0 and
~ ~
to suppress HMGR activity.2
P45oDM catalyzes the oxidative removal of the 14amethyl group of lanosterol I v via three NADPH-02dependent steps (Scheme 2, eq. 1) (20). T h e methyl group
is first oxidized to the hydroxymethyl moiety giving compound VI11 followed by oxidation to the corresponding
aldehyde IX. T h e third oxidative step, which results i i
the formation of 8,14-conjugated diene X with the loss of

Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutarylcoenzyme A;
HMGR, HMG-CoA reductase; HPLC. high Derformance liauid chrom a t o p p h y ; TLC, thin-layer cl"nography;
PPTS, pyridinium
..
p-toluenesulfonate; rt, room temperature; BsA, bovine serum albumin;
SDS, sodium dodecyl sulfate.
'To whom correspondence should be addressed at: Department of
Chemistry, Rensselaer Polytechnic Institute, Troy, NY 12180-3590.
21t should be noted that a comparison of the potencies of compounds
VIa&b and VI1 to those of other compounds reported to be inhibitors
of P 4 5 0 and
~ ~ suppressors of HMGR activity is difficult as different
cell lines and assay systems were used in the studies.
I
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the l5a-proton and formic acid, appears to proceed via an
enzyme-bound peroxyhemiacetal intermediate (21-23).
Lanosterol IV, 24,25-dihydrolanosterol XI, and lanost-7en-3D-01 XV appear to be substrates for P45oDM (24-28).3
Lanost-8-en-3P,32-diol XI1 and the corresponding A7isomer XVI have been shown to bind more tightly to
mammalian P 4 5 0 ~than
~ 24,25-dihydrolanosterol XI
( K , = 5.1 pM, 5.7 p M , and 32-35 p M for compounds
XII, XVI, and XI, respectively) (27). The oxidative
removal of C-32 is inhibited by aldehyde XI11 in rat liver
microsomes (29). In addition, 32-oxygenated lanosterol
analogs generated during the removal of the l4a-methyl
group by P45oDM (compounds XI1 and XIII) and their
A7-isomers (compounds XVI and XVII) have been
shown to decrease the activity of HMGR in Chinese

hamster lung cells (30). Trzaskos et al. (31) have recently
provided evidence that strongly suggests that aldehyde
XI11 is an endogenously generated regulator of HMGR
activity.
A variety of oxygenated cholesterol and lanosterol analogs have been shown to be potent suppressors of HMGR
activity. Based on the structures of these oxysterols, along
with information concerning the mechanism of P45oDM,
a series of oxolanosterol oximes and oxime ethers were
designed as potential suppressors of both HMGR activity
and inhibitors of P 4 5 0 ~ We
~ . present the synthesis and
evaluation of these potential dual-action inhibitors of cholesterol biosynthesis.

MATERIALS AND METHODS
31t should be noted that there appears to be a controversy over whether
or not A7-lanosterols are substrates for P45oDM. Akhtar'et d.(25, 26)
claim that 19a-3Hllanost-7-en-3B-ol
is a substrate and is converted to the
7J4-diene-in a &-free preparation from rat liver. Bossard et d. (27)
. ,
report a K, for lanost-7-ene~3J3,32-diol
in a reconstituted system utilizing purified P 4 5 0 ~ Sekigawa,
~.
Sonoda, and Sato (28), on the other
hand, state that lanost-7-ene-3(3,32-diolis not converted to 14-dehydroxymethylated products using a partially purified system.

General
' H NMR spectra were obtained on either a Varian
Unity-500 (500 MHz) or a Varian XL-200 l200 MHz)
tetramethylsilane as 'ainterni
NMR specirometer
standard. Infrared spectra were recorded On a Perkin
Elmer 298 spectrometer. Direct insertion probe (DIP)
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chemical ionization mass spectral data were obtained
3fl-Hydroxylanost-7-en-15-one
15-oxime (XIX)
High
from a Hewlett-Packard HP 5087 GC-MS
The general procedure was followed using 3fl-hydroxyperformance liquid chromatography (HPLC) was perlanost-7-en-15-one I11 (15) (90.0 mg, 0.2 mmol), absolute
formed using a Waters 6000A pump with either a Waters
ethanol (7.0 m]), pyridine (1.2 d,14.7 mmol), and
410 refractive index detector or a Waters Lambda-Max
N H 2 0 H . HC1 (250.0 mg, 3.6 mmol). The reaction was
481
uv detector.
stirred at reflux for 48 h. The residue was purified by flash
Points were determined On a Thomas Hoover
chromatography (Si(&, hexanes+=thyl acetate 5:1) giving
melting point apparatus and are uncorrected. Elemental
compound XIX (87.1 mg, 95%) as a white solid: mp
analyses were performed by Spang
183-185OC, lit 185-1860C (35) (EtOH/H,O); 1H NMR
ratories, Eagle Harbor, MI.
(CDC13, 500 MHz) 6 6.7 (brs, lH, NOH), 6.45 (m, lH,
reagents were purchased from A1drich
The
C-7-H), 3.26 (dd, J = 4.3 Hz, J = 11.4 Hz, 1H, C-3-H),
Chemical Company and were used as received: 7-dehydro2.77 (dd, J = 8.3 Hz, J = 20.0 Hz, 1H), 2.27 (dd, J = 7.8
hydroxy1amine
methoxylamine
Hz, J = 19.5 Hz, IH), 2.10-1.21 (m, 34H), 1.209 (s, 3H,
benzoxylamine
and
C-32-H), 0.987 (s 3H, C-30-H), 0.932 (d, J = 6.4 Hz,
bromide. Lanosterol was obtained from Sigma. 4-Chloro3H, c - ~ ~ - ~o.69
) , (s, 3H, c - ~ ~ - H ) lit
, ~ (34,35)5; IR
1-naphthol was obtained from Bio-Rad. Silica gel (EM
(CHC13) 3620 cm-1 (w), 2960 cm-' (s); MS (CI, isofor
Science Silica Gel 60, 230-400 mesh) was
butane) m/z 458 (M+1, 56%), 440 (M+1-H20, loo%),
flash chromatography (32). ~L-3-[Glutaryl-3-~~C]hydroxy422 (M+1-2H20, 34%).
3-methylglutaryl coenzyme A (60 mCi/mmol), L[3,4,5-3H]leucine (176.5 Cilmmol), RS-[5-3H]mevalono3fl-Hydroxylanost-7-en-15-one
15-methyloxime
lactone (24 Cilmmol), and sodium [l-l4C]acetate (59 mCi/
(XXIII)
mmol) were obtained from DuPont-New England Nuclear.
The general procedure was followed using 30-hydroxyThe HMGR.activity experiments used Silica Gel Si-250
lanost-7-en-15-one I11 (15) (60.0 mg, 0.14 mmol), absolute
thin-layer chromatography (TLC) plates obtained from
ethanol (4.0 ml), pyridine (0.17 ml, 2.1 mmol), and
Baker. Nitrocellulose membranes (0.45 p ) were obtained
NH2OCH3. HCl (40.0 mg, 0.5 mmol). The reaction was
from Schleicher and Schuell. Cab-0-Si1 M-5 hydrated
stirred at reflux for 48 h. The residue was purified by flash
colloidal silica was from Kodak. McCoy's 5a medium was
chromatography ( S O 2 , 5:l hexanes-ethyl acetate) giving
from Gibco and fetal bovine serum was from MA Biocompound XXIII (32 mg, 51%) as a white solid: mp
products. ITS' was from Collaborative Research. Digito139-141OC (EtOH/HZO); 'H NMR (CDC13, 500 MHz)
nin (Fisher) was used as a 10 mg/ml stock solution in 50%
6 6.60-6.50 (m, l H , C-7-H), 3.87 (s, 3H, NOCH3),
ethanol. Pyridinium p-toluenesulfonate (PPTS) was pre3.35-3.15 (m, lH, C-3-H), 2.686 (dd, J = 8.3 Hz, J = 19.0
pared as described by Miyashita, Yoshikoshi, and Grieco
Hz, lH), 2.197 (dd, J = 9.2 Hz, J = 19.1 Hz, lH),
(33). Anti(HMG-CoA reductase) IgG was a generous gift
2.16-1.20 (m, 22H), 1.197 (s, 3H, C-32-H), 0.991 (s, 3H,
from Dr. Gene C. Ness, University of South Florida,
C-30-H), 0.922 (d, J = 6.4 Hz, 3H, C-21-H), 0.898 (s,
Tampa, FL. The peroxidase-conjugated goat anti-rabbit
3H, C-29-H), 0.894 (s, 3H, C-lg-H), 0.867 (d, J = 6.8
IgG was obtained from Jackson Immunoresearch. AR45
Hz, 3H, C-27-H), 0.862 (d, J = 6.3 Hz, 3H, C-26-H)
cells were a generous gift from Dr. Harry W. Chen,
0.686 (s, 3H, C-18-H)4; IR (CHC13) 3600 cm-' (w),
DuPont Merck Pharmaceutical Company.
2960 cm-' (s); MS (DIFCI, isobutane) d z 472 (M+l,

Chemical synthesis, general procedure for the
preparation of oximes
An oven-dried round-bottom flask with stirring bar was
charged with the appropriate ketone or aldehyde, absolute
ethanol, and dry pyridine. The required hydroxylamine
hydrochloride ( N H 2 0 H . HCl, N H 2 0 C H 3 .HC1, or
NH20CH2C6H5.HCl) was added as a solid. The flask
was equipped with a condensor with a septum and a gasneedle inlet and flushed with argon. The mixture was
stirred at reflux under argon for the given period of time
and cooled to room temperature (rt). Water was added
and the ethanol was removed in vacuo. The residue was
extracted well with CH2C12.The combined organic layers
were dried with anhydrous Na2S04, fiitered, and the solvent was removed in vacuo. The residue was purified by
flash chromatography ( S O 2 ) with the indicated eluant.
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54%), 455 (M+l-HzO, 70%), 440 (M+l-CH,OH,
100%). Anal. calcd for C31H53N02:
C, 78.92; H, 11.32; N,
2.97. Found: C, 78.77; H, 11.44; N, 2.98.

4The assignment of methyl group resonances in the IH NMR spectra
of the compounds described herein were based on those reported by
Emmons, Wilson, and Schroepfer (55) for similar lanasterol analogs.
5We have found that the chemical shifts of the NOH protons in the
'H NMR spectra vary with concentration; therefore, it is difficult to
compare our chemical shift data for the oxime protons with those
reported (34, 35). O u r 1H NMR spectral data for compound XXX is
consistent with that reported by the DuPont group (35). O u r assignment
of the C-7 proton of compound XIX (6 6.45) is in agreement with that
reported by Dolle et al. (34). Gaylor and coworkers (35) report a
resonance at this chemical shift (6 6.44, 1H) but assign the C-7 proton
to a resonance at 6 6.85. O u r assignment of the C-3-H (6 3.25-3.35) is
consistent with that reported by Gaylor and coworkers (6 3.26) (35).
Dolle et al. (34) report the C-3-H for compound XIX at 6 3.45.

3~-Hydroxylanost-7-en-15-one
15-benzyloxime
(XXIV)
Method A: The general procedure was followed using
30-hydroxylanost-7-en-15-oneI11 (15) (67.0 mg, 0.15
mmol), absolute ethanol (4.0 ml), pyridine (0.19 ml,
2.3 mmol), and NH20CH2C6H5- HCI (90.0 mg, 0.5
mmol). The reaction was stirred at reflux for 48 h. The
residue was purified by flash chromatography ( S O 2 , 5:l
hexanexethyl acetate) giving compound XXIV (74 mg,
90%) as a white solid: mp 149-152OC (CH3CN); 1H
NMR (CDCI3, 500 MHz) 6 7.45-7.25 (m, 5H, Ar-H),
6.55-6.45 (m, lH, C-7-H), 5.14-5.09 (m, 2H, PhCH,),
3.30-3.15 (m, lH, C-3-H), 2.728 (dd, J = 8.6 Hz,
J = 19.3 Hz, lH), 2.230 (dd, J = 9.0 Hz, J = 19.3 Hz,
lH), 2.15-1.20 (m, 22H), 1.196 (s, 3H, C-32-H), 0.992 (s,
3H, C-30-H), 0.916 (d, J = 6.4 Hz, 3H, C-21-H), 0.895
( s , 3H, C-29-H), 0.884 (s, 3H, C-lg-H), 0.863 (d,
J = 6.4 Hz, 3H, C-27-H), 0.858 (d, J = 6.9 Hz, 3H,
C-26-H), 0.659 (s, 3H)4; I R (CHC13) 3600 cm-l (w),
2950 cm-l (s); M S (DIFCI, isobutane) d z 548 ( M + l ,
4%), 531 (M+l-HZO, 8%), 440 ( M + ~ - O C H Z C ~29%),
H~,
107 (OCH2C6H5, 100%). Anal. calcd for C37H57N02:
C,
81.12; H , 10.49; N, 2.56. Found: C, 81.17; H, 10.69; N,
2.57.
Method B: An oven-dried round-bottom flask with stirring bar was charged with potassium hydride (0.05 g,
35% dispersion in mineral oil, 0.44 mmol). The flask was
equipped with a septum and a gas-needle inlet and
flushed with argon. Dry dimethoxyethane (DME) (1 ml)
was added via syringe and the slurry was cooled to
OOC. 30-Hydroxylanost-7-en-15-one 15-oxime XIX
(80.0 mg, 0.18 mmol) in dry DME (1 ml) was added dropwise and the mixture was stirred at O°C for 15 min.
Benzylbromide (52 pl, 0.44 mmol) was added dropwise.
The mixture was allowed to warm to room temperature
and stirred for 25.5 h. The DME was removed in vacuo
and the residue was dissolved in water and petroleum
ether. The organic layer was removed and the aqueous
layer was extracted well with petroleum ether. The combined organic layers were washed with saturated NaCl
solution and dried with anhydrous MgS04. Filtration,
concentration, and purification by flash chromatography
( S O z , 9:l hexane:ethyl acetate) gave 15-benzyloxime
XXIV (57 mg, 58%) with physical and spectroscopic
characteristics identical to those given above.
3P-Hydroxylanost-8-en-7-one7-oxime (XXVI)

The general procedure was followed using 30-hydroxylanost-8-en-7-one XXV (36) (150.0 mg, 0.34 mmol), absolute ethanol (5.6 ml), pyridine (0.42 ml, 5.2 mmol), and
NH,OH.HCl (85.0 mg, 1.2 mmol). The reaction was
stirred at reflux for 30 h. The residue was purified by flash
chromatography ( S O z , 5:l hexanes-ethyl acetate) giving
compound XXVI (93.2 mg, 60%) as a white solid: mp

176-178'C (EtOH); 'H NMR (CDCl3, 500 MHz) 6 7.4
(brs, lH, NOH), 3.260 (dd, J = 4.7 Hz, J = 11.5 Hz, lH,
C-3-H), 3.194 (dd, J = 3.9 Hz, J = 17.1 Hz, lH),
2.30-0.89 (m, 39H), 0.868 (d, J = 6.8 Hz, 3H, C-27-H),
0.863 (d, J = 6.4 Hz, 3H, C-26-H), 0.710 (s, 3H,
C-18-H)4; IR (CHC13) 3580 cm-l (m), 3320 cm-l (w),
2900 cm-1 (s), 1585 cm-1 (w); MS (CI, isobutane) d z 458
( M + l , 87%), 440 (M+l-H20, loo%), 422 (M+1-2H&,
14%). Anal. calcd for C30H51N02:C, 78.72; H, 11.23; N,
3.06. Found: C, 78.94; H, 11.29; N, 3.14.

30-Hydroxylanost-8-en-7-one
7-methyloxime (XXVII)
The general procedure was followed using 30-hydroxylanost-8-en-7-one XXV (36) (112.0 mg, 0.25 mmol),
absolute ethanol (5.0 ml), pyridine (0.31 ml, 3.8 mmol),
and NHzOCH3 HCl (75.0 mg, 0.9 mmol). The reaction
was stirred at reflux for 48 h. The residue was purified by
flash chromatography @ioz, 1O:l hexanes-ethyl acetate)
giving compound XXVII (84.9 mg, 72%) as a white
solid: mp 115-117OC (CH3CN); 'H NMR (CDC13,
500 MHz) 6 3.865 ( s , 3H, NOCH3), 3.237 (dd, J
4.2
Hz, J = 11.6 Hz, lH, C-3-H), 3.071 (dd, J = 3.9 Hz,
J = 17.1 Hz, lH), 2.30-0.92 (m, 42H), 0.911 (d, J =
6.0 Hz, 3H, C-21-H), 0.712 ( s , 3H, C-18-H)4; IR
(CHC13) 3450 cm-l (w), 2950 cm-l (s), 1580 cm-' (w),
1030 cm-1 (m); MS (CI, isobutane) d z 472 (M+l, 31%),
457 (M+1-CH3, 31%), 440 (M+1-CH30H, 18%). Anal.
calcd for C31H53N02:
C, 78.92; H, 11.32; N, 2.97. Found:
C, 78.99; H, 11.40; N, 2.99.
+

3/3-Hydroxylanost-7-en-32-al
32-oxime (XXX)
The general procedure was followed using 30-tetrahydropyranyloxylanost-7-en-32-al
XXVIII (37-40) (50.0 mg,
0.095 mmol), absolute ethanol (3.0 ml), pyridine (0.12 ml,
1.5 mmol), and N H 2 0 H HCl(24.0 mg, 0.34 mmol). The
reaction was stirred at reflux for 4 h. The residue was
purified by flash chromatography (Si02, 5:l hexanesethyl acetate) giving two compounds: 30-tetrahydropyranyloxylanost-7-en-32-al32-oxime XXIX (11 mg,
22%) as a white solid: IH NMR (CDC13, 200 MHz)
6 7.80-7.70 (m, 1H); 7.30-7.20 (m, lH), 5.45-5.35 (m,
lH), 4.80-4.70 (m, 1/2H), 4.60-4.50(m, 1/2H), 4.00-3.85
(m, lH), 3.55-3.40 (m, lH), 3.30-3.20 (m, 1/2H),
3.15-3.00 (m, 1/2H), 2.10-0.80 (m, 48H), 0.70 (s, 3H);
and 3P-hydroxylanost-7-en-32-al
32-oxime XXX (34 mg,
77%) as a white solid: mp 209-211OC (CHzCl2-hexane),
lit 212.5-214.5OC (35) (EtOH/H,O); lH NMR (CDC13,
500 MHz) 6 7.767 (s, lH, C-32-H); 7.264 (m, lH,
NOH), 5.45-5.35 (m, lH, C-7-H), 3.245 (dd, J = 4.4
Hz, J = 11.3 Hz, lH, C-3-H), 2.15-0.98 (m, 41H), 0.977
(s, 3H, C-30-H), 0.710 (s, 3H, C-18-H)4; lit (35)5; IR
(CHC13) 3580 cm-l (w), 2950 cm-l (s); MS (DIPCI,
isobutane) d z 458 (M+1,63%), 440 (M+l-HzO, loo%),
413 (M+l-H-CH,NOH, go%), 395 (M-CHZNOH+
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H 2 0 , 88%). Anal. calcd for C31H53N02:C, 78.72; H ,
11.23; N, 3.06. Found: C, 78.54; H, 11.20; N, 3.19. The 30tetrahydropyranyloxylanost-7-en-32-al32- oxime XXIX
(11.3 mg, 0.02 mmol) was converted to 3P-hydroxylanost7-en-32-a1 32-oxime XXX by treatment with PPTS
(10.0 mg, 0.04 mmol) in absolute ethanol (4 ml) at rt overnight. The ethanol was removed in vacuo. Water was
added to the residue and the mixture was extracted well
with CH2C12. The combined organic layers were dried
with anhydrous Na2S04,filtered, and the solvent was removed in vacuo. The residue was purified by flash chromatography (Si02, 5:l hexane-ethyl acetate) to give
3/3-hydroxylanost-7-en-32-al 32-oxime XXX (9.5 mg,
0.02 mmol) with physical and spectroscopic characteristics identical to those given above. Total yield (0.043 g,
0.094 mmol) 99%.

3~-Hydroxylanost-7-en-32-al32-methyloxime
(XXXI)
The general procedure was followed using 30-tetrahydropyranyloxylanost-7-en-32-al
XXVIII (37-40) (50.0 mg,
0.15 mmol), absolute ethanol (3.0 ml), pyridine (0.12 ml,
1.5 mmol), and N H 2 0 C H 3 .HCl (29.0 mg, 0.34 mmol).
The reaction was stirred at reflux for 2 h. The residue was
purified by flash chromatography ( S O P , 15:l hexanesethyl acetate) giving compound XXXI (38 mg, 84%) as
a white solid: mp 124-126OC (CH3CN); lH NMR
(CDC13, 500 MHz) 6 7.712 (s, lH, C-32-H), 5.45-5.35
(m, lH, C-7-H), 3.811 (s, 3H, NOCH3), 3.30-3.15 (m,
l H , C-3-H), 2.10-0.80 (m, 41H), 0.970 ( s , 3H, C-30-H),
0.698 ( s , 3H, C-18-H)4; IR (CHC13) 3600 cm-l (w),
2950 cm-1 ( s ) ; MS (DIPCI, isobutane) m/z 472 (M+1,
84%), 454 (M+l-HZO, loo%), 440 (M+l-CH30H,
50%), 413 (M+l-CHZNOCH3, 73%), 395 (M+l-H,OCH2NOCH3, 62%). Anal. calcd for C31H53N02:C,
78.92; H, 11.32; N, 2.97. Found: C, 78.77; H, 11.35; N,
3.09

Biochemical evaluation. Assay of lanosterol
14a-methyl demethylase ( P 4 . 5 0 ~ activity
~)
The assay of P450Dh.f developed by Trzaskos et al. (20)
was used in these studies. Briefly, dihydrolanosterol XI
(33 pM) and varying concentrations of the potential inhibitors (suspended with the aid of Tyloxapal) were incubated with rat liver microsomal protein, 0.2 mM NAD,
0.1 mM NADH, 0.3 mM NADP, 2.0 mM NADPH,
10 mM isocitrate, isocitrate dehydrogenase (0.25 unitdm1
final volume), 0.4 mM magnesium chloride, 50 pM
AY-9944, and 1 mM sodium cyanide in 0.1 mM phosphate
buffer (containing 1 mM glutathione, 0.1 mM EDTA,
pH 7.4, 20% glycerol) at 37°C for 45 min. The reactions
were stopped by the addition of 15% potassium hydroxide
(w/v) in 95% methanol. The resultant mixtures were
heated in boiling water for 30 min and the nonsaponifiable material was extracted with petroleum ether.
The petroleum ether was blown off with nitrogen, the
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residue was dissolved in absolute ethanol, and the lanosta8,14-dien-3P-01XIV content was determined by high performance liquid chromatography using a UV detector
(acetonitrile-methanol-water
45:45:10, 1.5 ml/min,
Ultrasphere octyl column, X = 254 nm).

Cell culture
Chinese hamster ovary (CHO-K1) cells were grown in
a 5% C O P atmosphere in modified McCoy's 5a medium
supplemented with 1% delipidated fetal bovine serum
prepared by Cab-O-Si1 treatment (41). Cultures were routinely passaged twice weekly by trypsinization. P45oDMdeficient (AR45) cells (42) were maintained in modified
McCoy's 5A medium supplemented with 5% fetal bovine
serum. Cells were refed with fresh medium containing 1%
ITS' (a chemically defined serum-free medium supplement) 16 hr prior to assay. Test compounds were added as
bovine serum albumin (BSA) suspensions from stock solutions in absolute ethanol. The final concentration of
BSA was 0.5 mg/ml and the final ethanol concentration
did not exceed 0.5%.

[14C]Acetate incorporation into saponifiable and
nonsaponifiable lipids
The [ 14Clacetate incorporation studies were carried out
as described previously (43). Briefly, exponentially growing cultures were labeled with [l-lCIacetate, and harvested into ice-cold saline. An equal volume of 15% KOH
in 90% methanol containing 100 pglml butylated hydroxytoluene was added and samples were saponified at 85OC
for 30 min. Nonsaponifiable lipids were extracted with at
least 30 volumes of petroleum ether, washed once with 3%
N a z C 0 3and twice with water, and dried under nitrogen.
Extracts were analyzed by silica thin-layer chromatography (ethyl acetate-hexane 15:85). To measure incorporation into fatty acids, the aqueous phase was acidified, extracted with petroleum ether, and an aliquot was counted
in a liquid scintillation counter.

HMG-CoA reductase enzyme activity
This assay has been described in detail previously (44).
Briefly, cells were plated in 24-well cluster plates, grown
for 2 days, and permeabilized by incubation for 5 min at
room temperature with 30 pg/ml digitonin in cytoskeletal
(CSK) buffer (0.3 M sucrose, 0.1 M KC1, 2.5 mM M&12,
1 mM EGTA, 10 mM PIPES, pH 6.8). The digitonin solution was removed and the permeabilized cells were incubated for 20 min at 37°C in pre-incubation buffer
(50 mM phosphate buffer, pH 7.4, 10 mM dithiothreitol,
1 mM EDTA). Alternatively, frozen cell pellets were sonicated in pre-incubation buffer and incubated at 37OC for
20 min. Reductase activity was determined by monitoring
the conversion of [ 14C]HMG-CoA to [14C]mevalonolactone, using [3H]mevalonolactone as an internal standard. The substrate and product were separated by thin-

which is a potent suppressor of HMGR activity (15)' and
appears to be an inhibitor of P45oDM (16).* Therefore,
15-oxime X I x was evaluated as an inhibitor of P45oDM
and as a suppressor of HMGR activity. It should be noted
Immunoblot analysis of HMGR protein
that during our evaluation of compound XIX, Dolle,
Quantitative immunoblot analysis of cells was perAllandeen, and Kruse (34) reported the synthesis of this
formed as described previously (44). Cells were solubicompound as an intermediate in the preparation of azalized by scraping directly into sodium dodecyl sulfate
D-homosterols. In addition, Gaylor and coworkers (35) at
(SDS)-urea sample buffer, heated at 90°C for 3 min, and
DuPont have independently studied compound XIX as
frozen at -8OOC. Proteins were separated by SDSan inhibitor of cholesterol biosynthesis.6
15-Oxime XIX was prepared by oximation of ketone
polyacrylamide gel electrophoresis on 10% slab gels. Proteins were electroblotted onto a 0.45 p nitrocellulose memI11 which is available from 7-dehydrocholesterol XXII in
brane in 49.6 mM Tris, 384 mM glycine, 20% methanol,
9 steps (15, 45). The 15-position of ketone I11 is quite hin0.0375% SDS at 0.4 A for 16 h. Membranes were blocked
dered and a large excess of hydroxylamine hydrochloride
by washing in 5% nonfat dry milk in TBS/Tween (20 mM
in the presence of pyridine at an elevated temperature for
2 days was required for the reaction to proceed to compleTris, 500 m M NaCl, 0.05% Tween 20, p H 7.5) HMGR
t i ~ n The
. ~ inhibition of P45oDM by 15-oxime XIX was
was detected using a polyclonal anti(HMGR) antibody,
assessed using a modification of the assay developed by
and visualized using a peroxidase-conjugated second antiTrzaskos and coworkers (20). Briefly, this assay utilizes
body. Bands were visualized with 4-chloro-1-naphthol according to the manufacturer's instructions. Immunoblots
24,25-dihydrolanosterol XI as the substrate and quantitates the build-up of diene XIV by UV-HPLC. As rat
were quantitated by scanning with a LKB laser densitometer and immunoreactive protein expressed as the area
liver microsomal preparations are used, the pathways by
under the absorbance curve.
which diene XIV is degraded must be inhibited. The
reduction of the Al*-double bond of diene XIV, the next
step in the cholesterol biosynthetic pathway, is inhibited
RESULTS AND DISCUSSION
by AY-9944 and the removal of the methyl groups at C-4
is blocked by the addition of cyanide. A plot of turnover-'
versus inhibitor concentration obtained by varying the
During our pursuit of the synthesis of various 15concentration of inhibitor at constant substrate concensubstituted lanosterol derivatives as potential cholesterollowering agents, we prepared 3/3-hydroxylanost-7-en-15-one tration (24,25-dihydrolanosterolXI, 33 pM) was used to
15-oxime XIX (34, 35).5.6 This oxime lacks the 15adetermine the IC50
value for the inhibitor. An IC50
value
of 3.0 pM was obtained for 15-oxime XIX in this manner
proton that is required for the removal of the 14a-methyl
(Table 1). This result suggests that 15-oxime XIX is an
group by P45oDM and is therefore a substrate analog that
is incapable of being completely metabolized to the coreffective inhibitor of P45oDM ( K , of 24,25-dihydrolanosterol XI is 33 p M under the assay conditions) and is
responding diene. If 15-oxime XIX is accepted as a substrate by P 4 5 0 ~ ~
l4a-hydroxymethyl
,
and 14a-formyl
similar in potency to ketone I11 (IC50 = 7.1 p M , Table 1).
compounds (Le., compounds XX and XXI) would be
It should be noted that 15-oxime XIX, and all of the other
formed. These compounds may be effective inhibitors of
oximes that we have studied, are stable for extended
P45oDM since, as mentioned earlier, alcohol XI1 and
periods of time in phosphate buffer at 37OC and to the
aldehyde XI11 (eq. 1 in Scheme 2) have been shown to insaponification conditions utilized in the rat liver P45oDM
hibit the loss of (2-32 in rat liver microsomes. Furtherassays (KOH/methanol at 100°C for 30 min). Evidence
more, 15-oxime XIX is similar in structure to ketone I11
for the inhibition of P45oDM in intact cells by 15-oxime

layer chromatography on Silica Gel Si-250 plates, visualized with I2 vapors, scraped, and counted. Protein concentrations were determined with Bio-Rad protein reagent.

6Ko and coworkers at DuPont have independently studied 15-oxime

XIX as an inhibitor of cholesterol biosynthesis. Their results are
described in their recent patent (35) (date of patent: August 20, 1991).
They report an IC50 value for suppression HMGR of 0.2 p~ and an
ICso value for inhibition of P45oDM of 55 pM. w e presented the preliminary results on the inhibition of P45oDM and suppression of
HMGR activity by 3/3-hydroxylanost-7-en-15-one
15-oxime (compound
XIX) at the 201" ACS meeting on April 16, 1991. The IC5o value we
obtained for inhibition of P45oDM is different from the value reported
by the DuPont group. This difference may be due to differences in the
assay conditions. We have found our IC50 value to be reproducable (5 x )
and it is consistent with the data we obtained in C H O cells.

'Schroepfer et al. (15) report an IC50 value for 15-ketone I11 of
0.8 pM in mouse L cell cultures which is in close agreement with our
results in C H O cell cultures (0.5 p ~ ) .
8Morisaki et al. (16) report 15-ketoneI11 as an inhibitor of the conversion of dihydrolanosterol XI to cholesterol in the S-10 fraction of a rat
liver homogenate. An ICso value w a s not provided.
gEach of the oximes and oxime ethers described herein appears to be
one stereoisomer. All of the oximes exhibit a single peak for the oxime
hydrogen and the oxime methyl ethers exhibit singlets for the methyl
group in their 'H NMR spectra. In addition, the C-18 methyl group is
a singlet in all cases.
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TABLE 1. IC,, values for inhibition of P 4 5 0 and
~ ~ HMGR
activity by oxylanosterols and oxolanosterol oximes

I11

XIX'
XXIII
XXIV

xxv

XXVI
XXVII
XXX'
XXXI

In vitroa

CHOh

CHO'

AR45'

7. l d
3.0
77
101
0.57h
21
28
8.9
102

0.7
2.0
> 20
> 20
> 20
> 20
> 20
1.o
> 20

0.5'
06
15.0
15.0
0.9
6.7
> 20
1 .o
10.0

1.8
1.5
> 20
nd'
8
19
nd'
2
> 20

"Assays performed using rat liver microsomal preparations
'Chinese hamster ovary cells.
'P-450~M-deficientcell line.
'See footnote 8.
'See footnote 7.
'See footnote 6.
<Not determined.
%ee footnote 10.
'See footnote 1 1

XIX was provided by [ I4C]acetate incorporation studies
(43). Exponentially growing cells were treated with increasing concentrations of inhibitor, pulsed with [l-'+C]acetate,
and the 14C-radiolabelednonsaponifiable lipids were analyzed by thin-layer chromatography. Results from a representative experiment are shown in Figure 1. 15-Oxime
XIX caused a reduction in the incorporation of [14C]acetate into material with the chromatographic behavior of
C27 monohydroxysterols. This decrease was accompanied
by an increase in radioactivity in the region of the chromatogram corresponding to the migration of authentic
lanosterol (C30). The reduction of incorporation of radiolabel into C27 sterols with the concommitant increase in
radiolabeled C30sterols is consistent with the inhibition of
P45oDM by 15-oxime XIX. Plots of the data from this
study (Fig. 1) were used to calculate the concentration of
inhibitor that resulted in an equal incorporation of 14C
radioactivity into CZ7and C30 sterols. The average value
obtained from two independent experiments is given in
Table 1. Compound XIX at concentrations up to 20 PM
had no effect on the incorporation of [14C]acetate into
fatty acids.
An initial screening of the effects of 15-oxime XIX on
HMGR activity in C H O cells indicated that it is a potent
suppressor of HMGR activity. Exponentially growing
cells were treated for 4 h with compound XIX and
H M G R activity was determined in permeabilized cells or
cell sonicates by monitoring the conversion of [ 14C]HMGCoA to [ l+C]mevalonate, using [3H]mevalonolactone as
an internal standard (44). The results of concentration
studies of 15-oxime XIX versus HMGR activity in both
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Fig. 1. Changes in sterol labeling profiles in C H O cells treated with
15-oxime XIX. Cells were treated for 2 h with the indicated concentration of 15-oxime XIX and then labeled for an additional 2 h with
1 pCi/ml [l-'+C]acetate. Nonsaponifiable lipids were extracted and fractionated by T L C as described in the text. Incorporation of [1-'4CJacetate
sterols is expressed as a percentage of the total
into C,, (W) and CZ7(0)
incorporation into nonsaponifiable lipids. Values for incorporation into
total nonsaponifiable lipids decreased with increasing sterol concentration. Values were 28.1 dpm/pg cell protein in control cultures and
8.1 dpmlpg protein at a sterol concentration of 20 p ~ .

normal CHO and P450~~-deficient
(AR45) cells (42)
are shown in Figure 2 and Table 1. The concentration of
inhibitor required to reduce HMGR activity to 50% of
control in C H O cells was found to be 600 nM. The ability of compound XIX to suppress HMGR activity is similar in both C H O cells and in AR45 cells. These results
suggest that the suppression of HMGR by compound
XIX is independent of its effects on P45oDM. Com~
pounds that are competitive inhibitors of P 4 5 0 ~can

40
h
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'E 30

Ea
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...''.7
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. . .100

Concentration (pM)
Fig. 2.

H M G R activity in C H O and AR45 cells treated with 15-oxime

XIX. Wild type (CHO) and lanosterol l4a-methyl demethylase
( P 4 5 0 ~ ~ ) - d e f i c i e (AR45)
nt
cells were treated for 4 h with increasing
concentrations of 15-oxime XIX. H M G R activity was then assayed in
permeabilized cells as described in Materials and Methods. Data
represent the mean and standard error of four determinations: (0)
CHO; (W) AR45.

cause the build-up of the natural intermediates XI1 and
XIII, which in turn suppress HMGR activity. If compound XIX was acting by this mechanism, it would not

H M G R activity. Studies are underway to determine the
mechanism by which 15-oxime XIX regulates HMGR
gene expression.
In an attempt to assess whether or not the oxime hydrobe expected to suppress H M G R activity in AR45 cells.
The addition of 15-oxime XIX to C H O cell sonicates at
gen is required for the inhibitory properties of compound
XIX, the corresponding 15-methyl- and 15-benzyloximes
concentrations up to 5 BM had no effect on H M G R ac(compounds XXIII and XXIV) were studied.
tivity, demonstrating that this compound is not a direct
15-Methyloxime XXIII was prepared from ketone 111 in
inhibitor of HMGR. The effect of compound XIX on
a manner analogous to that discussed previously for comH M G R protein concentration was determined by quantipound XIX using methoxylamine hydrochloride instead
tative immunoblot analysis (44). Comparisons of the
of hydroxylamine hydrochloride (for examples of preparareduction of H M G R activity versus HMGR protein
tion of oxime ethers by treatment of a ketone or aldehyde
levels with increasing 15-oxime XIX concentration in
with alkyloxylamine hydrochlorides or treatment of oxiC H O and AR45 cells are shown in Figure 3. The parallel
mates with an alkylating agent, see references 47 and 48).
decline in HMGR activity and protein levels suggests that
compound XIX suppresses HMGR activity in both cell
15-Benzyloxime XXIV was prepared either in the same
manner using benzoxylamine hydrochloride or by treatlines by regulating gene expression. The suppression of
ment of 15-oxime XIX with potassium hydride followed
H M G R protein levels by 15-oxime XIX is not due to
by benzyl bromide (48). The 15-methyl- and 15-benzylnonspecific inhibition of cellular protein synthesis as the
oximes were evaluated for inhibition of P45oDM and suptreatment of cells with the oxime at concentrations up to
5 p M had no effect on the incorporation of [3H]leucine
pression of HMGR activity. The results of these studies
are summarized in Table 1. Both the 15-methyl- and
into total acid-precipitable proteins. These results demon15-benzyloximes, compounds XXIII and XXIV, were
strate that, as predicted, 15-oxime XIX is indeed a dualsignificantly less active than 15-oxime XIX in their ability
action inhibitor of cholesterol biosynthesis that causes
to suppress H M G R and P 4 5 0 ~
activities
~
in cultured
both the inhibition of P 4 5 0 ~and
~ a reduction in
cells. In the in vitro assay for P45oDM activity, 15-methylH M G R activity and protein concentration.'j This is in
oxime XXIII was considerably less active than 15-oxime
contrast to the results reported by Schroepfer et al. (46)
for the oxime of 3~-hydroxy-5a-cholest-8(14)-en-15-one. XIX; 15-benzyloxime XXIV was the least active of the
three. These results suggest either that the oxime hydroThe ICso value for suppression of H M G R activity in
mouse L cells was reported to be 0.2 p M for this comgen is important for the inhibitory properties of compound XIX or that the larger methyl and benzyl groups
pound. However, this oxime does not appear to suppress
are inhibiting the binding of the oxime to the active site
other enzymes in the cholesterol biosynthetic pathway as
of P45oDM as well as interfering with the ability of these
it exhibited comparable effects on the incorporation of
compounds to regulate HMGR gene expression. It is also
[ 14Clacetate into digitonin-precipitable sterols and on
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Concentration-dependent suppression of H M G R activity and protein in cells treated with 15-oxime XIX.Wild type (CHO) and lanosterol
14a-methyl demethylase (P45O~~)deficient(AR45) cells were treated for 4 h with increasing concentrations of 15-oxime XIX. H M G R activity was
determined in permeabilized cells as described in Fig. 2. H M G R protein levels were determined by quantitative immunoblot analysis as described
in Materials and Methods, with data representing the average and range of duplicate determinations; (0)activity; (B) immunoreactive protein.

Fig. 3.
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possible that there is a difference in the stereochemistry
about the C-N bond for the oxime versus the oxime
ether^.^
In light of the results with 15-oxime XIX, oxolanosterol
oximes at positions other than C-15 were pursued. Sato
and coworkers (49-52) have reported that 30-hydroxylanost-8-en-7-one xxv is an inhibitor of P45oDM. Based
on this report, 30 -hydroxylanost-8-en-7-one 7 -oxime
XXVI was prepared by treatment of ketone XXV with
hydroxylamine hydrochloride. Ketone XXV was prepared as described by Pinhey and coworkers (36) in five
steps from lanosterol IV. The effects of 7-oxime XXVI on
P 4 5 0 and
~ ~ HMGR activities are summarized in Table 1.
This oxime exhibits an ICs0 value of 21 pM for inhibition
of P45oDM in the rat liver microsomal preparation assay,
suggesting that it is not as effective an inhibitor of
P 4 5 0 as
~ ~15-oxime XIX. In accordance with the results
reported by Sat0 and coworkers (49-52),10 we found
7-ketone XXV to be a potent inhibitor of P 4 5 0 in
~ ~the
same assay system (IC50 = 0.57 p M ) . However, both the
7-oxime XXVI and the 7-ketone XXV at concentrations
up to 20 pM had little effect on the incorporation of
[ l*C]acetate into CZ7sterols and C30sterols in C H O cells.
This is not surprising in regard to the 7-oxime XXVI as
its inhibitory activity in the in vitro (rat liver microsomal
preparations) assay was limited. However, the discrepancy between the inhibition of P450DM by 7-ketone
XXV in the in vitro versus the cultured cells studies suggests that this ketone may be metabolized to a compound
that is incapable of inhibiting P 4 5 0 ~ As
~ . can be seen in
Table 1, both the 7-ketone and the 7-oxime cause the suppression of HMGR activity with ICs0values in C H O cells
of 0.9 and 6.7 p M , respectively. Quantitative immunoblot
analysis similar to that shown in Fig. 3 revealed that suppression of HMGR by compounds XXV and XXVI was
occurring at the level of gene expression (data not shown).
To our knowledge, this is the first report of 7-substituted
lanosterol analogs acting as suppressors of HMGR activity. The potency of 7-ketone XXV as a suppressor of
HMGR activity is similar to that of the 15-oxime XIX
and the 15-ketone 111 discussed previously, suggesting
that if 7-ketone XXV is being metabolized by the cells,
the metabolite is acting as a suppressor of HMGR activity. This putative metabolite may be similar in structure
to 7-ketocholesterol or 4,4-dimethyl-3P-hydroxycholest5-en-7-one (53, 54), known suppressors of HMGR activity. Reported ICs0 values for suppression of HMGR
activity by these compounds in mouse L cells were

lowe have included our data for the inhibition of P 4 5 0 ~
by ~3Phydroxylanost-8-en-7-oneXXV in Table 1 since Sat0 and coworkers
value or a Ki for this compound in rat
(49-52) do not report a n IC5o
value of 0.2-0.3pM
liver microsomal preparations. They report an ICso
for inhibition of P 4 5 0 ~by~ 3~-hydroxylanost-8-en-7-one
XXV in
Saccharomyces cereuisiae.
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3.7 p~ and 1.5 p M , respectively (53, 54). However, suppression of HMGR activity by 7-ketone XXV in the
demethylase-deficient AR45 cell line suggests that this
compound can suppress HMGR activity in the absence of
active P45oDM. Experiments to investigate the
metabolism of 7-oxylanosterols in C H O cells are in progress. 7-Methyloxime XXVII was prepared in the same
manner as 15-methyloxime XXIII. As can be seen in
Table 1, 7-methyloxime XXVII is not very effective in
causing the inhibition of P45oDM or the suppression of
HMGR activity. This decrease in potency when the oxime hydrogen is replaced with a methyl group is consistent with the results for the 15-substituted compounds
XIX and XXIII.
32-Oxime XXX" is similar in structure to both the alcohol and aldehyde intermediates generated during the
removal of the 14a-methyl group (;.e., compounds XI1
and XIII) which are known inhibitors of P45oDM (29)
and suppressors of HMGR activity (30). Treatment of 30tetrahydropyranyloxylanost-7-en-32-alXXVIII (37-40)
with hydroxylamine hydrochloride in the presence of pyridine gave a mixture of 3~-tetrahydropyranyloxylanast-7en-32-a1 32-oxime XXIX and the desired 3-deprotected
32-oxime XXX. The 3/3-tetrahydropyranyloxylanost-7en-32-a1 32-oxime XXIX was easily deprotected to give
32-oxime XXX by treatment with pyridinium p-toluenesulfonate (PPTS) in ethanol (33). 32-Oxime XXX was
found to be an inhibitor of P45oDM exhibiting an ICso
value of 8.9 p M in vitro and 1.0 p M in cultured cells
(Table 1). It is also a potent suppressor of HMGR activity
with an IC50 value of 1.0 pM in C H O cells and 2.0 p M in
P450~~-defiCient
(AR45) cells. 32-Methyloxime XXXI
was also prepared in a manner analogous to the preparation of compound XXIII (Table 1). Once again, the
replacement of the hydrogen of the oxime moiety with a
methyl group greatly diminished the activity of the oxime
for both inhibition of P 4 5 0 ~and
~ suppression of
HMGR activity.

CONCLUSION

A series of oxolanosterol oximes and oxime ethers have
been prepared as potential dual-action inhibitors of
cholesterol biosynthesis. 3P-Hydroxylanost-7-en-15-one
15-oxime XIX was found to be an effective inhibitor of
P45oDM in both rat liver microsomal preparations and in
C H O cells. In addition, 15-oxime XIX was shown to
suppress HMGR activity by regulation of gene expression. These results demonstrate that, as predicted,

"This compound is included in DuPont's patent (35). They report an

IC5ovalue for suppression of HMGR of 1.4 pM and an ICsovalue for
inhibition of P450DM of 3.0 p ~ .

15-oxime XIX is indeed a dual-action inhibitor of
cholesterol biosynthesis that causes both the inhibition of
P 4 5 0 and
~ ~ a reduction in HMGR activity. Oximes at
C-7 and C-32 also exhibited inhibition of both P45oDM
a n d HMGR activity. I n all cases, replacement of the
oxime hydrogen with a methyl group greatly reduced the
activity of the oxime for both inhibition of P45oDM and
suppression of HMGR activity. I
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